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Breast cancer continues to be a disease with tremendous public health significance. Pri-
mary prevention of breast cancer is still not available, so efforts to promote early detection
continue to be the major focus in fighting breast cancer. Since early detection is asso-
ciated with decreased mortality, one would think that it is important to minimize delays
in detection and diagnosis. There are two major types of delay. Patient delay is delay in
seeking medical attention after self-discovering a potential breast cancer symptom. System
delay is delay within the health care system in getting appointments, scheduling diagnostic
tests, receiving a definitive diagnosis, and initiating therapy. Earlier studies of the conse-
quences of delay on prognosis tended to show that increased delay is associated with more
advanced stage cancers at diagnosis, thus resulting in poorer chances for survival. More
recent studies have had mixed results, with some studies showing increased survival with
longer delays. One hypothesis is that diagnostic difficulties could perhaps account for this
survival paradox. A rapidly growing lump may suggest cancer to both doctors and patients,
while a slow growing lump or other symptoms could be less obvious to them. If this is the
case, then the shorter delays would be seen with the more aggressive tumors for which
the prognosis is worse leading to reduced survival. It seems logical that a tumor that is
more advanced at diagnosis would lead to shorter survival but the several counter-intuitive
studies in this review show that it is dangerous to make assumptions.
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INTRODUCTION
Breast cancer continues to be a disease with tremendous public
health significance. It is estimated that in the United States in
2014 approximately 232,670 cases of female breast cancer will be
diagnosed, and approximately 40,000 women will die from the
disease, making breast cancer the second leading cause of can-
cer deaths in women (1). Primary prevention of breast cancer is
still not available except by extreme measures such as prophylac-
tic mastectomy for women who are genetically at high risk, so
efforts to promote early detection continue to be the major focus
in fighting breast cancer. The goal of early detection is to diagnose
and treat breast cancer patients in an early stage when the prog-
nosis for long-term survival is best. Prognosis is generally more
favorable for women with early stage disease than for those with
more advanced disease. Since early detection is associated with
decreased mortality, one would think that it is important to mini-
mize delays in detection, diagnosis, and treatment. Longer waiting
times prior to breast cancer diagnosis and the initiation of therapy
are of prognostic concern if delay leads to stage progression, dis-
ease worsening, or treatment complications. There are two major
types of delay. Patient delay is delay in seeking medical attention
after self-discovering a potential breast cancer symptom or fail-
ure to keep appointments. System delay is delay within the health
care system in getting appointments, scheduling diagnostic tests,
receiving a definitive diagnosis, and initiating therapy. Both of
these, by leading to delays in diagnosis and treatment, could result
in a poorer prognosis for women with breast cancer.
A comprehensive review of the literature on delay in breast can-
cer done in the early 90s consisted of several components (2). The
first part of the review examined studies that explored the rela-
tionship between delay and prognosis. The review then shifted to
the importance of patient delay and the factors that are associated
with long patient delay. It did the same thing with system delay.
Since that time, a number of review articles have been published
exploring the factors associated with long delay (3–5). The author
therefore decided to focus this review on the impact of delay on
survival from breast cancer.
EARLY STUDIES
Earlier studies of the consequences of delay on prognosis tended
to show that increased delay is associated with more advanced
stage cancers at diagnosis, thus resulting in poorer chances for
survival. In fact, a meta-analysis of 87 studies suggested strongly
that women who begin treatment 3–6 months after the appear-
ance of breast cancer-related symptoms have significantly worse
survival than women who wait <3 months (6). However, most of
those studies were old, with a majority taking place prior to 1970.
Two studies that took place in the late 1990s that were included in
the review are discussed below among the recent studies (7, 8).
A number of additional studies from the 80s that were not
included in the review by Richards et al. also showed that increased
delay was associated with more advanced tumors at diagnosis
and/or reduced survival. Robinson et al. looked at delay in diagno-
sis among breast cancer patients and found that those with delays
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of at least 6 weeks had more advanced disease (35% stage I, 52%
stage II, and 12% stage III) than those with delays of <6 weeks
(52% stage I, 42% stage II, and 5% stage III) (9). Survival was
not determined in this study. Neale et al. demonstrated that even
without adjustment for tumor grade, patients at Houston’s M.D.
Anderson Hospital with delay of more than 6 months had substan-
tially lower cumulative survival after 10 years than patients with
delay of 3–6 or<3 months (10). In a study of breast cancer patients
at New York’s Memorial Sloan-Kettering Cancer Center, Pilipshen
et al. reported that among patients treated by radical or modified
radical mastectomy in 1970–1971 and 1980–1981 combined, those
delaying more than 6 months were approximately twice as likely to
have tumors of at least 4 cm and approximately 40% more likely to
have axillary metastases than patients delaying≤6 months (11). In
a study of 274 Los Angeles breast cancer patients, increased relative
risks for regional disease were observed in the interval between self-
discovery of the symptom and first contact with the physician up
to 5 months (12). In addition, regional disease was associated with
the interval between self-discovery of the symptom and biopsy,
but not with the interval between the first contact with the physi-
cian and biopsy. The authors found that once the patient was seen
by the doctor, there was no evidence that further delays adversely
affected the likelihood of being diagnosed with regional disease.
It is important to note that several very early studies from the
1940s to 1950s had not detected the expected inverse relationship
between delay and survival (13, 14). In response, Bloom showed
that this was largely due to confounding by histologic grade or the
inherent malignant potential of the cancers (15). In an analysis
of breast cancer cases from the Middlesex Hospital in London, it
appeared that women with long delay were more likely to have less
aggressive cancers.
RECENT STUDIES
Among the more recent studies, the results are mixed. One group
of studies analyzes the relationship between delay and tumor stage
at the time of initiation of therapy. One may infer that women
with more advanced tumors will, on average, have shorter sur-
vival. Other studies analyze the relationship between delay and
survival time, sometimes without considering tumor stage. These
two types of studies are reviewed separately.
STUDIES OF DELAY AND TUMOR STAGE
Plotogea et al. performed two studies in which longer delay was
found to be associated with lower stage at diagnosis. In one of
the studies, out of a random sample of 2,615 women aged 50–69
with invasive breast cancer diagnosed between January 1, 1995 and
December 31, 2003, 2,065 were classified into three groups: screen-
detected breast cancer, if the patient had a mammogram during the
study period and her breast cancer was diagnosed within 6 months
of that screen; interval breast cancer, if the cancer occurred within
6–12 months of a mammogram; and symptomatic breast cancer, if
the cancer was detected in a woman who did not have a screen-
ing mammogram during the study period prior to diagnosis (16).
Screen-detected breast cancers diagnosed at stage II and sympto-
matic cancers diagnosed at stage III or IV had significantly shorter
diagnostic wait times (time from imaging or biopsy to breast can-
cer diagnosis) compared to those diagnosed at stage I (OR= 0.66,
95% CI= 0.50–0.87 and OR= 0.46, 95% CI= 0.25–0.85, respec-
tively). Plotogea’s other study included 1,760 women aged 50–69
diagnosed in Ontario with invasive breast cancer from 1995 to 2003
(17). The median delays were 17 days from diagnosis to definitive
surgery, 44 days from final surgery to postoperative chemother-
apy, and 75 days from final surgery to postoperative radiotherapy.
Of note is the finding that diagnosis during 2000–2003 was associ-
ated with significantly longer delay for each phase of the treatment
pathway compared to 1995–1999. Higher stage at diagnosis was
associated with shorter wait times from diagnosis to definitive
surgery (stage III versus I: OR= 0.49, 95% CI= 0.34–0.71).
Warner et al. conducted a study on 21,427 White, Hispanic,
Black, and Asian women diagnosed with stage I–IV breast cancer
between January 1, 2000 and December 31, 2007 at a National
Comprehensive Cancer Network Center (18). Among the symp-
tomatic women, median time to diagnosis ranged from 36 days in
Whites to 53.6 days in Blacks, while among women with abnormal
mammograms, median time to diagnosis ranged from 21 days in
Whites to 29 days for Blacks. Blacks had the highest proportion of
stage III or IV tumors (26%). After accounting for time to diag-
nosis, the observed increased risk of stage III and IV breast cancer
was reduced from 40 to 28% among Hispanics and from 113 to
100% among Blacks, but estimates remained statistically signif-
icant. Longer time to diagnosis did not completely explain the
observed differences in stage between racial/ethnicity groups.
Two hundred Libyan women, aged 22–75 years, with breast can-
cer diagnosed during 2008–2009 were interviewed about their
diagnosis delay [interval from the date of the first symptoms to
the date of final breast cancer diagnosis based on histopathological
examination (19)]. The median diagnosis delay was 7.5 months,
as 30.0% of patients were diagnosed within 3 months after symp-
toms, 14% were diagnosed within 3–6 months, and 56% within
a period longer than 6 months. Diagnosis delay of >3 months
was associated with bigger tumor size, positive lymph nodes, high
incidence of late clinical stages, and metastatic disease.
A study examined the relationships between religiosity, spir-
ituality, breast cancer fatalism, disclosure of symptoms, marital
status, and time to seek medical care and breast cancer stage in
African-American women with self-detected breast changes (20).
A convenience sample of 129 African-American women aged 30–
84 who self-reported detecting a breast symptom before diagnosis
of breast cancer within the preceding 12 months were included in
the study. Most women delayed more than 3 months in seeking
medical care. No associations were found between religiosity, spir-
ituality, and fatalism and time to seek medical care. Women who
delayed seeking medical care for longer than 3 months were more
likely to present with a later stage of breast cancer than women
who sought care within 3 months of discovering their symptom.
A significant association was found between time to seek medical
care and breast cancer stage at diagnosis, as the longer the delay
the more advanced was the breast cancer stage (P = 0.01). Logistic
regression showed a significant positive association between delay
of symptom presentation for medical diagnosis and stage of breast
cancer (OR= 6.37, 95% CI= 2.84–14.30).
Redondo et al. performed a study of 411 breast cancer patients
who were histologically diagnosed at the Costa del Sol Hospital,
Marbella, Spain between January 1, 1996 and December 31, 2001
Frontiers in Public Health | Child Health and Human Development July 2014 | Volume 2 | Article 87 | 2
Caplan Delay in breast cancer
to evaluate the influence of emergency admission and delays on
prognosis (21). Total delay was divided into three components.
Patient and primary care delay was defined as the interval from first
symptom to first visit to hospital; diagnostic delay as the interval
from first hospital visit to definitive histopathologic diagnosis, and
treatment delay as the interval from diagnosis to first treatment.
The median delay times were 87, 11, and 36 days, respectively.
Patient and primary care delay of >6 months was associated
with advanced stages, although these tumors presented patho-
logic characteristics of good prognosis, such as positive estrogen
and progesterone-receptor status and non-ductal type. In con-
trast, a diagnostic delay of <30 days was significantly associated
with increased tumor size, lymph node metastasis, and ductal type
(P < 0.05), and with a negative progesterone-receptor status and
poorly differentiated tumors (P < 0.01). The authors attributed
this to sicker patients receiving prompt medical attention. Treat-
ment delay of <30 days was significantly associated with ductal
type, negative hormone receptor status, and the presence of signs
or symptoms other than a lump (P < 0.05).
Elzawawy et al. performed several studies between 1984 and
2007 looking at the delay in seeking medical advice and the patho-
logical tumor size of female breast cancer patients in Port Said,
Egypt (22). Over the years, there was a decline in delay, and there
was also a decline in advanced cases.
Elmore et al. conducted a retrospective cohort study on 400
female breast cancer patients diagnosed between 1985 and 1993
and followed through June 20, 2001 (23). Among the 117 women
with patient-detected breast cancer, those who completed their
evaluation within 30 days were significantly more likely to have
local disease at diagnosis (83%) than women taking more than
30 days to have an evaluation who were more likely to be diagnosed
with regional disease (36%,P < 0.05). Women taking>30 days for
an evaluation were significantly more likely to have a breast can-
cer recurrence or death than women who had an evaluation in
<30 days (24 versus 8%; P < 0.05).
Patient delay (time from onset of first symptoms to first con-
sultation of a doctor) and its impact on stage of disease were
examined in a population-based study of 287 women aged 18–80
with newly diagnosed invasive symptomatic breast cancer (24).
Median patient delay was 16 days among symptomatic patients,
and 18% of all breast cancer patients had patient delay longer than
3 months. The results demonstrated a difference in the associa-
tion between patient delay and stage at diagnosis of breast cancer
when stratified by tumor differentiation. For women with well
differentiated tumors, the proportion of late-stage breast can-
cer did not change with increasing patient delay (P trend= 0.83),
but for women with poorly differentiated tumors, a monotonic
trend between length of patient delay and late-stage diagnosis was
observed (P trend= 0.03).
In a study to examine the extent and determinants of patient
and general practitioner delay in the presentation of breast can-
cer, 185 cancer patients attending a breast unit were interviewed
2 months after diagnosis (8). Patient delay in presentation to the
general practitioner was 12 or more weeks in 19% of the patients
and was related to clinical tumor size ≥4 cm (P = 0.0002) and
with a higher incidence of locally advanced and metastatic disease
(P = 0.01).
Lannin et al. conducted a case–control study of patients diag-
nosed as having breast cancer at the University Medical Center of
Eastern Carolina from 1985 through 1992 (25). There were a total
of 540 patients and 414 matched controls from the community.
It was found that delaying seeing a physician because of money
was a predictor of advanced breast cancer stage (OR= 1.6, 95%
CI= 1.1–2.5).
STUDIES OF DELAY AND SURVIVAL
Treatment delay (the number of weeks between the date of diagno-
sis and date of definitive treatment) was evaluated in a retrospec-
tive case-only study on 8,860 adolescent and young adult breast
cancer cases diagnosed from 1997 to 2006 using the California
Cancer Registry database (26). The 5-year survival in women who
were treated by surgery and had treatment delay of more than
6 weeks was 80% compared with 90% (P = 0.005) in those with
treatment delay of<2 weeks. In multivariate analysis, longer treat-
ment delay was a significant risk factor for shorter survival. The
adverse effect of increased treatment delay on survival was more
pronounced in African-American women, those with public or no
insurance, and those with low socioeconomic status.
McLaughlin et al. conducted a retrospective analysis of 1,786
low-income, adult female North Carolina Medicaid enrollees diag-
nosed with breast cancer from January 1, 2000 to December
31, 2002, in the linked North Carolina Central Cancer Registry-
Medicaid Claims database to study the impact of long delay
between a biopsy-confirmed breast cancer diagnosis and treat-
ment initiation on survival (27). The median delay was 22 days.
Adjusted Cox proportional hazards regression demonstrated that
the delay interval did not affect survival among those diagnosed
at an early stage, but among late-stage patients, intervals between
diagnosis and first treatment ≥60 days were associated with sig-
nificantly worse breast cancer-specific survival (HR= 1.85, 95%
CI= 1.04–3.27; P = 0.04).
In a study of 553 patients in Pittsburgh with breast cancer
metastasis, treatment delay was defined as the time in days between
the date of diagnosis of initial breast cancer metastasis (the date
of first metastatic biopsy or CT scan) and the date of the initiation
of first treatment (28). Treatment delays of over 12 weeks were
related to adverse survival outcomes.
Brazda et al. conducted a retrospective review of patients under-
going breast cancer treatment between August 2005 and December
2008 in a comprehensive, multidisciplinary breast oncology pro-
gram in two hospital systems (29). The patients were divided into
three groups based on interval to treatment (the time between date
of pathological diagnosis, usually via core needle biopsy, and the
date of initial therapy, either surgical or systemic): 0–45, 46–90,
and >90 days, and there was no association between the interval
to treatment and survival. Because previous studies had revealed
decreased survival with delays >90 days, the authors separated
patients into groups based on interval to treatment of <90 and
>90 days, but there was no demonstrable difference in survival
between these two groups.
Smith et al. conducted a study of 314 participants in South
Carolina’s Breast and Cervical Early Detection Program between
1996 and 2004 to assess differences in factors associated with breast
cancer mortality in African-American as compared to European
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American women (30). The study looked at three delay intervals,
diagnostic delay, treatment delay, and total delay. The diagnostic
delay was the time interval between the date of the first screening
examination (clinical breast exam or mammography) that found
an abnormality and the date of the pathologic diagnosis of breast
cancer within that screening cycle. Treatment delay was the time
interval between the date of the pathologic diagnosis of breast can-
cer and the date of the initiation of the first course of treatment.
There was no significant association between the risk of death and
the delay intervals using Cox Proportional Hazards models.
Hershman et al. conducted a study in women in the Henry Ford
Health System tumor registry who were diagnosed with stage I/II
breast cancer between January 1, 1996 and December 31, 2001 and
who received adjuvant chemotherapy (31). An observed/expected
ratio of treatment duration and completed chemotherapy cycles
was calculated for each patient. Among the 344 patients receiving
the expected number of cycles, 60% experienced delays, but these
delays did not reduce survival. However, the authors cautioned
that only 17% of the patients had delays longer than 2 weeks, so
perhaps the delays may not have been long enough to affect sur-
vival or perhaps the study may have been underpowered to detect
their effects.
Sainsbury et al. conducted a retrospective analysis of breast can-
cer patients listed in the Yorkshire Cancer Registry to investigate
whether delays by providers in routine practice for diagnosis influ-
ence survival (32). Information for 36,222 patients with breast
cancer from 1976 to 1995 was available. Patients were grouped
according to the time from family physician referral to treatment,
with the times being <30, 30–59, 60–89, and 90 days or more.
Median delay between first hospital visit and treatment nearly dou-
bled from 7 to 13 days between 1976 and 1995, while the median
delay from family physician referral to hospital visit changed only
from 10 to 12 days in the same time period. Patients with delays
<30 days between family physician referral and treatment had
worse survival than patients with the longer delay time periods
(P < 0.001).
In a study of 7,608 patients with primary breast cancer, patient’s
and doctor’s delays were arbitrarily divided into short (0–14 days),
intermediate (15–60 days), and long (>60 days) (33). A long
patient’s delay was associated with an unfavorable outcome when
compared with a short patient’s delay, but the opposite was true
for doctor’s delay as the prognosis was better for patients with
long doctor’s delay compared to those with short doctor’s delay. In
addition, when corrected for age, the prognostic value of delay on
mortality increased by 24% for a long patient’s delay compared to
a shorter one and by 13% for a short doctor’s delay compared to a
longer one. The authors suggested that the doctor’s delay findings
indicate that doctors are capable of distinguishing between more
and less aggressive malignancies.
Richards et al. conducted a study of 2,964 women who pre-
sented with any stage of breast cancer to Guy’s Hospital in London
between 1975 and 1990 (7). A total of 32% of the women had
symptoms for at least 12 weeks prior to their first hospital visit.
Among these women, 32% had locally advanced or metastatic dis-
ease, compared to 10% of those women with delays of <12 weeks.
Women with delays of 12–26 weeks had significantly worse sur-
vival rates than those with <12 weeks of delay. In multivariate
analyses, the adverse impact of delay on survival was attributable
to an association between longer delays and more advanced stage,
but this adverse impact disappeared within individual stages of
disease.
CONCLUSION
Despite the prevalence of studies suggesting that long delays are
associated with poorer survival, given the mixed results for the
more recent studies, it is hard to make a case one way or another for
longer delay leading to reduced survival. It seems counter-intuitive
that longer delays should be associated with earlier stage cancers
and/or increase survival compared to shorter delays. However,
there are a number of possible explanations for this phenome-
non. One explanation is that diagnostic difficulties could perhaps
account for this survival paradox (34). A rapidly growing lump
may suggest cancer to both doctors and patients, while a slow
growing lump or other symptom could be less obvious to them.
If that were the case, then one would expect to see less delay in
the woman with the symptom that is more suggestive of cancer.
So the biological characteristics of the tumor might be the dri-
ver of the poorer survival, as opposed to the short delay. Another
possible explanation could be that a study did not have enough
“long” delayers to have adequate power. A suggestion to that effect
was made by Hershman et al. regarding their study. Finally, it is
possible that the delay intervals that were used in some studies
to categorize “long” delayers were just not long enough to have a
negative effect on survival. That coupled with one or both of the
other explanations could help explain how some studies showed a
protective effect of delay.
One notes that there are more studies of delay as it relates to
tumor stage or size than there are of studies that focus on delay
as it relates to survival. This may be explained by the greater diffi-
culty of conducting studies of survival. Tumor staging occurs early
in the course of treatment, while survival cannot be determined
until the death of the patient. However, studies of survival prob-
ably deserve greater credence. It seems logical that a tumor that
is more advanced at diagnosis would lead to shorter survival; but
the several counter-intuitive studies in this review show that it is
dangerous to make assumptions.
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